Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 3/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141609 | 0.82 | ABL1 (0.35) | ABL1ATRBRAF | |
| SCHEMBL1141291 | 0.80 | ABL1 (0.35) | ABL1ATR | |
| SCHEMBL5808054 | 0.76 | ABL1 (0.34) | ABL1ATRBRAF | |
| SCHEMBL5812270 | 0.74 | ABL1 (0.34) | ABL1ATRBRAF | |
| SCHEMBL5821921 | 0.74 | CNR2 (0.35) | ABL1ATRBRAF | |
| SCHEMBL1141496 | 0.72 | ABL1 (0.34) | ABL1ATR | |
| SCHEMBL1141303 | 0.71 | ABL1 (0.34) | ABL1ATR | |
| SCHEMBL1141497 | 0.71 | ATR (0.34) | ABL1ATRBRAF | |
| SCHEMBL1141151 | 0.70 | ABL1 (0.35) | ABL1ATR | |
| SCHEMBL1141305 | 0.70 | ABL1 (0.33) | ABL1ATRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232308-B2 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2012-07-31 | — | — | US | disclosed |
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039891-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, ROCK2 | ABL1 67/4885ATR 2910/4885BRAF 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.